Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases.
( 1
min )